AP1G1 Knockout HeLa Polyclonal Cells are a population of CRISPR/Cas9-edited HeLa cells with targeted disruption of the AP1G1 gene, which encodes the gamma-1 adaptin subunit of the adaptor protein complex 1 (AP-1). This polyclonal pool provides a heterogeneous knockout model, avoiding clonal selection artifacts and enabling immediate phenotypic studies. The cells are supplied as a ready-to-use population for loss-of-function analyses in membrane trafficking.
HeLa cells are a human cervical adenocarcinoma line, positive for human papillomavirus 18 (HPV18). They are a foundational model in cell biology, characterized by rapid proliferation, well-defined endocytic and secretory pathways, and high transfection efficiency. Their epithelial origin and transformed phenotype make them particularly suited for studying intracellular sorting, cancer cell biology, and therapeutic responses.
The AP-1 complex, composed of gamma, beta1, mu1, and sigma1 subunits, is a central mediator of clathrin-dependent vesicle formation at the trans-Golgi network (TGN). AP1G1 encodes gamma-1 adaptin, which is recruited to TGN membranes by ARF1-GTP and regulated by PKD-mediated phosphorylation. The complex recognizes sorting motifs in cargo cytoplasmic tails, including mannose-6-phosphate receptors (IGF2R and M6PR), directing them into clathrin-coated vesicles for delivery to endosomal compartments. Additionally, AP-1 interacts with clathrin triskelia and other cofactors. Disruption of AP1G1 impairs TGN-to-endosome trafficking, leading to defective lysosomal enzyme sorting, altered recycling of receptors like beta-secretase (BACE1), and broad perturbations in membrane protein homeostasis.
In HeLa cells, AP1G1 knockout results in compromised endosomal and lysosomal function, manifesting as mislocalization of lysosomal hydrolases and aberrant surface expression of receptors. Given the role of trafficking dysregulation in cancer??impacting processes such as growth factor receptor recycling, secretion of proteases, and drug efflux??this model offers a valuable system to dissect AP-1?Cdependent contributions to cancer cell phenotypes. The polyclonal nature avoids potential off-target clonal effects, yielding robust population-level insights into trafficking deficits.
Typical applications include immunofluorescence using markers for TGN and endosomes, western blotting to assess proteolytic maturation of lysosomal cargo proteins, flow cytometry to monitor surface receptor abundance, and live-cell trafficking assays with VSVG-GFP reporter. The cells are also amenable to clathrin-coated vesicle purification and lysosomal enzyme activity measurements. These approaches enable detailed interrogation of AP-1 function in lysosomal biogenesis, cancer cell secretion, and drug resistance mechanisms. For further information, please contact Ascent Research.
